SPECT/CT Could Prevent Unnecessary Surgery for Kidney Tumors
By MedImaging International staff writers Posted on 02 May 2017 |
Researchers have shown that a non-invasive imaging exam, 99mTc-sestamibi SPECT/CT, together with a regular CT or MRI scan, can prevent unnecessary surgery for many patients with benign kidney tumors.
The 99mTc-sestamibi Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) scan provides additional diagnostic data, when used with conventional CT and Magnetic Resonance Imaging (MRI) scans, and helps clinicians distinguish between malignant and benign kidney tumors.
The results of the study were published in the April 2017 issue of the journal Clinical Nuclear Medicine. The study included 48 patients diagnosed with a kidney tumor using regular CT or MRI. The patients underwent an additional sestamibi SPECT/CT scan at Johns Hopkins University School of Medicine before surgery. Radiologists graded the tumors in both the conventional and the sestamibi SPECT/CT images as benign or malignant using a 5-point scale.
The researchers found that adding the sestamibi SPECT/CT scan helped identify seven out of nine benign tumors. The research also suggests that the sestamibi SPECT/CT test is a faster, and less expensive option than surgery. In the US alone, surgeons surgically remove benign kidney tumors in 5,600 patients every year.
One of the developers of the new approach, Steven P. Rowe, MD, PhD, at Johns Hopkins, said, “As radiologists, we have struggled to find noninvasive ways to better classify patients and spare unnecessary surgery, but this has not been easy. Sestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.”
The 99mTc-sestamibi Single-Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) scan provides additional diagnostic data, when used with conventional CT and Magnetic Resonance Imaging (MRI) scans, and helps clinicians distinguish between malignant and benign kidney tumors.
The results of the study were published in the April 2017 issue of the journal Clinical Nuclear Medicine. The study included 48 patients diagnosed with a kidney tumor using regular CT or MRI. The patients underwent an additional sestamibi SPECT/CT scan at Johns Hopkins University School of Medicine before surgery. Radiologists graded the tumors in both the conventional and the sestamibi SPECT/CT images as benign or malignant using a 5-point scale.
The researchers found that adding the sestamibi SPECT/CT scan helped identify seven out of nine benign tumors. The research also suggests that the sestamibi SPECT/CT test is a faster, and less expensive option than surgery. In the US alone, surgeons surgically remove benign kidney tumors in 5,600 patients every year.
One of the developers of the new approach, Steven P. Rowe, MD, PhD, at Johns Hopkins, said, “As radiologists, we have struggled to find noninvasive ways to better classify patients and spare unnecessary surgery, but this has not been easy. Sestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.”
Latest Nuclear Medicine News
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure
- New PET Radiotracer Aids Early, Noninvasive Detection of Inflammatory Bowel Disease